XENCOR (XE9 MU) stock market data APIs
€10.1845
0(0%)
as of March 12, 2026
Try our APIs with
free plan!
XENCOR Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for XE9.MU.
Prev. Close
10.1845
Open
10.1845
High
10.1845
Low
10.1845
52 wk Range
6.1-15.3
Market Cap
1 750 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get XENCOR data using free add-ons & libraries
Get XENCOR Fundamental Data
XENCOR Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-26
- EPS/Forecast: -0.58
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
XENCOR News
New
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
PASADENA, Calif., March 04, 2026--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune di...
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.62 per share a year ago. These figures are adjuste...
Xencor: Q4 Earnings Snapshot
PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Wednesday reported a loss of $6.7 million in its fourth quarter. The Pasadena, California-based company said it had a loss of...
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
-- XmAb819, novel first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody, Phase 1 dose expansion in CRC, NSCLC and pRCC open to enrollment; on track to present clinical data to support a recom...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
